Taiwan is mapping out a four-year national pharmaceutical resilience preparedness program that aims to bolster the country’s domestic drug supply with a 24 billion new Taiwan dollar ($755 million) | ...

In today’s Pharmaceutical Executive Daily, the FDA approves Hernexeos under a national priority voucher program, industry ...

Olema Pharmaceuticals (OLMA) stock plummeted 41% after Roche's Phase 3 breast cancer trial failed its primary endpoint, ...

Ron Lanton, Senior Partner & Global Strategist, Lanton, Lanton & Sosa Law PLLC, discusses FDA’s removal of the two-trial requirement marking a significant policy shift and prompting sponsors to ...

Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an update on its newly expanded hepatitis E virus (HEV) pipeline during its ...

Virginia state lawmakers who are tired of waiting are taking matters into their own hands during this year’s legislative ...

Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation ZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (Nasdaq: ...

Key Takeaways. Section 804 creates a legal pathway for states and tribes to import certain Canadian prescription drugs, contingent on demonstrable consumer savings and adherence t ...

ORLANDO, FL / ACCESS Newswire / February 27, 2026 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, ...

Bohen highlighted palazestrant as a “complete estrogen receptor antagonist” with an ~8‑day half‑life and high trough exposure, which Olema says supports continuous ER blockade, clean tolerability, and ...

This stock looks unstoppable right now.

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript March 5, 2026 Atea Pharmaceuticals, Inc. misses on ...